CinCor Pharma CEO Marc de Garidel (Eric Piermont/AFP via Getty Images)
October 12, 2021 10:56 AM EDTUpdated 11:13 AM
Financing

Qui­et Cin­Cor Phar­ma makes some noise with $143M, new tri­al plans for blood pres­sure drug

Nicole DeFeudis

Editor

Cin­Cor Phar­ma has been fair­ly qui­et since emerg­ing in the hy­per­ten­sion space a cou­ple of years ago with a for­mer Roche pro­gram in tow. Not …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times